Rs9828519

A pharmacogenetic study implicates SLC9A9 in multiple sclerosis disease activity.

An association was observed between rs9828519(G) and nonresponse to IFNβ treatment for multiple sclerosis (p discovery = 4.43 × 10e−8), which was then confirmed in a meta-analysis across 3 replication data sets (p replication = 7.78 × 10e−4).